Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest - Schedule of Noncontrolling Interest (Details)

v3.21.1
Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest - Schedule of Noncontrolling Interest (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
NCI - equity (deficit) - beginning of period $ (2,369)    
Net loss attributable to NCI (679) $ (436)  
NCI - equity (deficit) - end of period (2,246)   $ (2,369)
Non-controlling Interest [Member]      
NCI - equity (deficit) - beginning of period (2,369) $ (814) (814)
NCI - equity (deficit) - end of period (2,246)   (2,369)
Non-controlling Interest [Member] | Solys Diagnostics Inc. [Member]      
Net loss attributable to NCI (16)   (109)
Non-controlling Interest [Member] | Lucid Diagnostics Inc [Member]      
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise   5
Net loss attributable to NCI (663)   (1,503)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan $ 802   $ 52